Objective To evaluate the efficacy and safety of kidney-tonifying Chinese patent medicine in treating senile osteoporosis. Methods CNKI

CBM

VIP

Wanfang Database

Cochrane Library

MEDLINE

EMbase

Web of Science and database of clinical trials were searched to look for randomized controlled trials on kidney-tonifying Chinese patent medicine in treating senile osteoporosis. The selected clinical trials were evaluated by Cochrane evaluation criteria and tools and analyzed with Rev Man 5. 3. Results The kidney-tonifying Chinese patent medicine alone or combined with conventional Western medicine were better than the control group in improving total effective rate [RR =1. 22

95% CI（1. 08

1. 37）

I

2

= 57%

P = 0. 002; RR = 1. 12

95% CI（1. 05

1. 20）

I

2

= 7%

P =0. 0003]. While only several trials showed the kidney-tonifying Chinese patent medicines could increase serum levels of phosphate and calcium. Five trials reported that adverse reactions such as digestive symptoms occurred in Chinese patent medicine group

but no serious adverse reactions or adverse events. Conclusion The overall efficacy of kidney-tonifying Chinese patent medicine seems better than that of conventional Western medicine alone in treating senile osteoporosis

with good safety.